drugset / Trial / NCT05394415
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
NaSingle-groupOpen-labelTreatment
Summary
This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |